Gilead Sciences' Commitment to the COVID-19 Pandemic

Lee E, Osinusi A, Chokkalingam A, Brainard D, Tran T, Thrun M, Dau L, Wang C, Juneja K
Gilead Sciences, Inc.

EunYoung.Lee@Gilead.com
333 Lakeside Dr.
Foster City, CA 94404

Expanding Global Access to Effective Treatment

- **Production time optimized from 12 → 6 months**
- **Gilead donated entire supply of 1.5 M doses of RDV through June**
- **RDV approved or authorized for temporary use to treat COVID-19 in > 50 countries**
- **Meeting global demand of RDV supply to treat and stockpile for future spike in COVID-19 cases**


Jan
Globally sourcing critical starting materials and reagents
5K treatment courses available
May
RDV US EUA
RDV NDA Japan approval
Jun
1.5M doses donated
Jun-Jul
NDA approval in 8 countries
Jul
EU approval (conditional)
Aug
Voluntary licensing agreement with generic manufactures to expand RDV to 127 low and lower-middle income countries
Sep
500K doses available to US DHHS
Oct
RDV supply to meet real-time demand globally
Dec
> 2M treatment courses available
2020
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Increased supply > 50-fold since Jan 2020 and by 2021 there will be several million treatment courses

Research & Data Generation


Gilead Studies
Collaboration Studies
1st request 25 Jan
Compassionate Use
Prelim data 10 Apr
Pub 11 Jun
Start 22 Mar
EAP
NCT04323761
SoC RW Cohort
NCT04292899
Pub 24 Jul
Start 6 Mar
Simple Severe
NCT04292899
Prelim data 29 Apr
Pub 27 May
Start Sep
Inhaled
NCT04539262
Start Sep
Outpatient
NCT04501952
Start 15 Mar
Simple Moderate
NCT04292730
Pub 29 Aug
Start Jun
Peds (CARAVAN)
NCT04431453
Start 6 Feb
China CDC Severe
NCT04257656
Pub 29 Apr
Start 12 Feb
China CDC Moderate
NCT04252664
Start 30 Jul
NIAID ACTT-3
NCT04492475
Start 21 Feb
NIAID ACTT-1
NCT04280705
Prelim data 29 Apr
Pub 8 Oct
Start 8 May
NIAID ACTT-2
NCT04401579
Start 4 Aug
Lily (ACTIV-3)
NCT04501978
Start 22 Mar
WHO (Discovery)
NCT04315948
Start 31 Jul
I-SPY COVID
NCT04488081
Start 28 Mar
WHO (Solidarity)
NCT04321616
Start 28 May
Roche (REMDACTA)
NCT04409262
Jan 2020
Dec 2020

Clinical Trials & Data
6 Gilead Sponsored
11 Collaborative
15 Abstracts submitted
4 Publications

COMMIT™ Request for Proposal research grant program with >310 global submissions from 36 countries

Response to the global COVID-19 pandemic

Through multiple cross functional teams, Gilead supports governments, organizations, HCPs, patients to accelerate research, access to remdesivir (RDV), and collaborative education

> 10,000 patients
have received RDV through clinical trials

Resources

Patient Support

- Gilead COVID-19 Patient Disease Education infographic
- Support of independent medical education programs and downloadable patient material (WebMD, PRIME)

> 21,000
Responses to Med Info Inquiries from HCPs and patients

HCP Support

- > 60 Medical Information Global Response documents
- > 19 new educational Medical Affairs Slide decks on RDV and COVID-19 internal and HCP use
- Medscape and Clinical Care Options COVID-19 resources
  Webinars, Microlearning updates, Slide sets, FAQs

Online Resources:

Remdesivir.com, Gilead.com, AskGileadMedical.com

Global Community Support

Philanthropic funds to support nonprofit org.

Gilead CARES donations:
- $20M to nonprofit orgs. impacted by COVID-19
- $10M to healthcare systems and institutions to address the impact on the frontlines

Gilead matches employee donations to global relief funds to support COVID-19 efforts led by 3 premier orgs.

Direct Relief · United Nations Foundation · International Medical Corps

Gilead and Satcher Health Leadership Institute at Morehouse School of Medicine partnership to address COVID-19 disparities

Satcher Health Leadership Institute · SHLI · Morehouse School of Medicine

EUA, Emergency Use Authorization; EU, European Union; NDA, New Drug Application; EAP, Expanded Access Program; SoC, Standard of Care; RW, Real World; DHHS, Department of Human & Health Services

References:
1. Langreth, R. All Eyes on Gilead. Bloomberg BusinessWeek. 14 May 2020 **2**. Gilead Sciences Update On The Company's Ongoing Response To COVID-19.; 2020. Available at: https://www.gilead.com/purpose/advancing-global-health/covid-19. **3.** An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences.; 2020. Available at: https://stories.gilead.com/articles/an-open-letter-from-our-chairman-and-ceo-oct-8 **4**. Frequently Asked Questions on Remdesivir Pricing and Global Supply.; 2020. Available at: https://www.gilead.com/-/media/gilead-corporate/files/pdfs/covid-19/gilead-faq-remdesivir-pricing-final.pdf?la=en&hash=52132206BA6D59A29AAC853CE85FE27B **5.** Ongoing Support for Community Organizations.; 2020. Available at: https://www.gilead.com/purpose/advancing-global-health/covid-19/ongoing-support-for-community-organizations **6.** Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19.; 2020. Available at: https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-sciences-and-satcher-health-leadership-institute-at-morehouse-school-of-medicine-partner-to-study-racial-health-inequities-associated-with-covi **7.** Gilead Data on File

Special Thanks: **Becker M** (Medical Education & Program); **Desai P** (Clinical Operation); **Dinh T** (Med Info); **McKeel R** (Public Affairs); **Ngo D** (Graphics); **Nguyen K** (Project Management- Virology); **Sandhu S** (Med Info), **Zuka K** (Corporate Giving)